Galera to Present at H.C. Wainwright BioConnect Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that its President and CEO, Mel Sorensen, M.D., will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available via webcast on January 10 at 7:00 a.m. ET on Galera's Investors page. This event highlights the company's focus on developing novel therapeutics aimed at transforming cancer radiotherapy. Galera's lead product candidates include avasopasem manganese and rucosopasem manganese, which target radiotherapy-induced toxicities and enhance treatment efficacy.
- None.
- None.
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022.
A webcast of the presentation will be available for on-demand viewing on January 10, 2022 at 7:00 a.m. ET on the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 30 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities. The Company’s second product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.
Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com
William Windham
Solebury Trout
646-378-2946
wwindham@soleburytrout.com
Media Contact:
Zara Lockshin
Solebury Trout
646-378-2960
zlockshin@soleburytrout.com
FAQ
When will Galera Therapeutics present at the H.C. Wainwright BioConnect Conference?
What is the stock symbol for Galera Therapeutics?
Where can I watch the Galera Therapeutics presentation?
What are the main product candidates of Galera Therapeutics?
What is the purpose of Galera Therapeutics' product candidates?
